Pharmacy Claims Fraud Detection
43.4% of pharmaceutical spend shows detectable anomalies. Inspector AI identifies fraud, waste, and abuse patterns in your pharmacy claims using 25 specialized detection rules.
The Problem: Invisible Pharmaceutical Fraud in Latin America
Health insurers in Latin America face a quiet but significant challenge: fraud and abuse in pharmaceutical claims. Unlike traditional medical fraud where false claims may be obvious, pharmaceutical fraud hides in transactions that individually appear completely legitimate. Each dispensation has a valid prescriber, an in-formulary medication, and a patient with active coverage.
The problem is that traditional authorization systems evaluate each transaction in isolation. When a patient submits the same prescription for the fourth time in six months with exactly the same medications, each individual submission passes all validations. When a pharmacist systematically dispenses the brand version when a generic is available, each dispensation is technically correct. When a patient receives medications for conditions they have never been diagnosed with, the transaction is approved because the medication is on the formulary.
These patterns only become visible when the complete history of each patient, prescriber, and pharmacy is analyzed over time. Longitudinal analysis of claims data reveals systematic behaviors that no individual transaction review could detect. And the numbers are alarming: in our analysis of Latin American health insurance claims, 43.4% of pharmaceutical spend showed detectable anomalies.
These are not random errors or normal variations in medical practice. These are repetitive, systematic patterns indicating behavioral fraud, avoidable waste, and abuse of the pharmaceutical reimbursement system. The good news is that these patterns are detectable when the right analytical tools are in place.
What We Find: Five Categories of Anomalies
Inspector AI classifies pharmaceutical anomalies into five main categories, each with real metrics derived from the analysis of Latin American health insurance claims. These are not theoretical estimates — they are concrete findings based on actual dispensation data.
Waste and utilization represents 20.3% of anomalous spend. This includes early refills where patients request refills before their previous supply should be exhausted, same-molecule re-authorizations indicating unnecessary duplication, and same-day dispensations suggesting medication stockpiling. 1 in 16 subscribers show early refill patterns, and 1 in 5 subscribers show same-molecule re-authorizations.
Generic substitution opportunity represented 10.8% of anomalous spend on the book we analyzed. 96.8% of pharmaceutical spend went to branded drugs, even though 71% of branded products had a generic available. Less than 5% was dispensed as generic. And critically: 99.8% of those substitutions would have been clinically safe. The median savings per dispensation was $16, which on the ~50,000-subscriber book worked out to $4.53 million observed in one year.
Clinical mismatch represents 7.3% of anomalous spend. 1 in 6 subscribers received a drug with no diagnostic justification. 80% of these clinical flags are complete therapeutic area mismatches — not minor variations, but medications for entirely different body systems than the patient's diagnosis.
Behavioral fraud risk represents 4.6% of anomalous spend. This includes patterns such as cloned prescriptions — the exact same combination of medications resubmitted months later as if new — and cumulative doses exceeding safe limits. We have identified 433 subscribers with cumulative doses exceeding established safety limits.
Financial anomalies represent 0.4% of anomalous spend, involving price or billing patterns that do not correspond to expected market values.
43.4%
Spend with detectable anomalies
20.3%
Waste and utilization
10.8%
Generic substitution
7.3%
Clinical mismatch
4.6%
Behavioral fraud
0.4%
Financial anomaly
How It Works: Analysis Without Initial Integration
Inspector AI is designed to demonstrate value before requiring any system integration. The process begins with a proof of concept that can be completed in just 3 weeks, with no need to connect your internal systems.
The first step is uploading a sample of your pharmacy claims data. No integration with your management system is required — simply a historical data file. Inspector AI processes this data through its 25 specialized detection rules, each designed to identify a specific pattern of fraud, waste, or abuse.
The analysis generates a detailed report quantifying exactly how much spend shows anomalies and of what type. These are not generic alerts — each finding is backed by specific data: identified patients, involved transactions, amounts at risk, and detected patterns.
For organizations that want to go beyond retrospective analysis, Inspector AI offers real-time integration through a FHIR PAS (Prior Authorization Support) compatible API. This allows evaluation of each pharmacy claim at the point of dispensation, before payment is approved. The platform also integrates with customer service systems like Freshdesk and call centers to efficiently manage alerts.
The platform uses an OpenAI-compatible API, facilitating integration with existing workflows and allowing technical teams to build on the detection platform without depending on proprietary interfaces.
Financial Impact Observed on the Book: $5.1 Million in One Year
On the ~50,000-subscriber book we analyzed, the total financial impact observed was $5.1 million in one year. This figure is not a theoretical estimate — it is derived directly from median cost per transaction observed in that book's real claims data and the frequencies of each type of anomaly.
Generic substitution represents the single largest opportunity: $4.53 million per year, with a median of $16 per dispensation. Same-molecule re-authorizations contribute $244,000 annually with a median of $13 per dispensation. Early refills add $176,000 with a median of $41 per dispensation.
Clinical mismatches represent $126,000 per year with a median of $22 per dispensation. Excessive cumulative doses add $13,000 annually at a $14 median. Cloned prescriptions contribute $8,000 at a $26 median per transaction.
These numbers are conservative because they are based on medians, not averages. High-value outlier cases — which are frequently the most suspicious — would significantly increase these figures. Additionally, the non-financial impact is substantial: better quality of care, improved patient safety, and enhanced regulatory compliance.
Inspector AI was recognized with the International Innovation Award 2025 by the Fundacion Iberoamericana Alianza del Seguro in Monterrey, Mexico, validating the detection approach and methodology used.
$5.1M
Total annual impact observed on our 50K book
$4.53M/yr
Generic substitution
$244K/yr
Same-molecule re-auth
$176K/yr
Early refill
$126K/yr
Clinical mismatch
25
Detection rules
Why Inspector AI for Pharmacy Claims Fraud Detection
Pharmacy claims fraud detection requires a fundamentally different approach from traditional transactional authorization. Conventional systems evaluate each transaction in isolation — checking coverage, formulary, and authorization. This is necessary but insufficient.
Inspector AI complements your existing systems by providing the longitudinal analysis layer that reveals patterns invisible to transactional authorization. It does not replace your management system — it enhances it with intelligence that only emerges from data analysis over time.
The no-integration proof of concept means you can validate the platform's value in 3 weeks, with no risk or IT resource commitment. If the findings justify the investment, real-time integration via FHIR PAS allows moving from retrospective analysis to active prevention.
For health insurers in Latin America looking to reduce pharmaceutical losses in a measurable and rapid way, Inspector AI offers a clear path: demonstrate the problem with real data, quantify the financial impact, and provide the tools to resolve it.
Discover How Much You Lose to Pharmacy Fraud
Upload a sample of your claims data and receive a detailed anomaly report in 3 weeks. No system integration, no commitment.
Request Free Analysis